Unique ID issued by UMIN | UMIN000003884 |
---|---|
Receipt number | R000004674 |
Scientific Title | Multicenter clinical trial of nutritional Management in Reduced-Intensity Stem Cell Transplantation from An Unrelated Donor (with or without A Liquid Diet Containing Digested-form Oligopeptide) |
Date of disclosure of the study information | 2010/07/07 |
Last modified on | 2014/01/20 09:51:59 |
Multicenter clinical trial of nutritional Management in Reduced-Intensity Stem Cell Transplantation from An Unrelated Donor (with or without A Liquid Diet Containing Digested-form Oligopeptide)
NST-04
Multicenter clinical trial of nutritional Management in Reduced-Intensity Stem Cell Transplantation from An Unrelated Donor (with or without A Liquid Diet Containing Digested-form Oligopeptide)
NST-04
Japan |
hematological malignancies
Hematology and clinical oncology |
Malignancy
NO
To assess the efficacy and safety of oligopeptide in patients who underwent unrelated stem cell transplantation
Safety,Efficacy
Exploratory
Phase II
Probability of more than grade 3 intestinal toxicity up to 28 days after transplant
(1) 1-year overall survival and 1-year progression-free survival
(2) Total duration of more than grade 3 intestinal toxicity up to 28 days
(3) Treatment-related toxicity
(4) Engraftment
(5) Acute GVHD
(6) Infection
(7) Duration of TPN
(8) Dose and duration of intravenous molphine
(9) Total dose of insulin
(10) Hyperglycemia and hypoglycemia
(11) DAO activity
(12) Laboratory data (total protein, albumin, cholinesterase, pre-albumin, RBP, CRP, urinary creatinine)
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
NO
Central registration
2
Prevention
Food |
Patients will take oligopeptide from the beginning of conditioning regimen and up to 21 days after transplantation
Patients in non-oligopeptide group will not take oligopeptide
18 | years-old | <= |
70 | years-old | > |
Male and Female
(1) Patient with hematological malignancy which has the indication for the allogeneic transplant.
(2) Patient who receives an unrelated stem cell source
(3) Patient who can take oligopeptide
(4) Age from 18 to 70
(5) ECOG PS 0 or 1
(6) Patient who cannot tolerate myeloablative conditioning regimen
(7) Patient who had the informed consent
(8) Patient who expects to survive longer than 3 months
(1) Patient with severe organ dysfunction
(2) Patient with the postitivity of anti-HIV antibody
(3) Patient with uncontrolled infection
(4) Patient with pregnancy or breast feeding
(5) Patient with pshycological disease
(6) Patient with allergy against the drugs which are used for allogeneic transplant including chemotherapy and GVHD prophylaxis
(7) Patient with allergy against oligopeptide
76
1st name | |
Middle name | |
Last name | Sung-Won Kim |
National Cancer Center Hospital
Department of hematology
5-1-1, Tsukiji, Chuo-Ku, Tokyo
+81-3-3542-2511
skim@ncc.go.jp
1st name | |
Middle name | |
Last name | Sung-Won Kim |
National Cancer Center Hospital
Department of hematology
5-1-1, Tsukiji, Chuo-Ku, Tokyo
+81-3-3542-2511
skim@ncc.go.jp
Research supported by Ministry of Health, Labour and Welfare
Ministry of Health, Labour and Welfare
Japan
NO
国立がんセンター中央病院
2010 | Year | 07 | Month | 07 | Day |
Unpublished
Open public recruiting
2010 | Year | 07 | Month | 01 | Day |
2010 | Year | 07 | Month | 01 | Day |
2013 | Year | 06 | Month | 01 | Day |
2010 | Year | 07 | Month | 07 | Day |
2014 | Year | 01 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004674